Caris Life Sciences, the Irving-based biotech company, announced Thursday that it closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion.
Caris, a molecular science and technology company that is actively developing and delivering innovative solutions to revolutionize healthcare, said it will use the proceeds to repay debt, improve its unique precision medicine platform, and for general corporate purposes....
MORE►
